Bristol-Myers Squibb (NYSE:BMY) Updates FY 2024 Earnings Guidance

Bristol-Myers Squibb (NYSE:BMY) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.400-0.700 for the period, compared to the consensus EPS estimate of 0.650. The company issued revenue guidance of -. Bristol-Myers Squibb also updated its FY24 guidance to $0.40-0.70 EPS.

Analyst Ratings Changes

BMY has been the topic of several research reports. BMO Capital Markets reduced their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a market perform rating on the stock in a report on Friday. Redburn Atlantic downgraded Bristol-Myers Squibb from a buy rating to a neutral rating and lowered their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Bank of America cut shares of Bristol-Myers Squibb from a buy rating to a neutral rating and reduced their price target for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an equal weight rating on the stock in a research note on Friday. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a strong-buy rating to a buy rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Hold and an average target price of $60.00.

Bristol-Myers Squibb Trading Up 0.4 %

Shares of NYSE BMY traded up $0.16 during trading hours on Friday, reaching $44.86. The stock had a trading volume of 21,279,666 shares, compared to its average volume of 15,968,238. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The business’s fifty day moving average price is $51.13 and its two-hundred day moving average price is $51.26. The firm has a market cap of $90.92 billion, a price-to-earnings ratio of 11.70, a P/E/G ratio of 1.47 and a beta of 0.39. Bristol-Myers Squibb has a 52-week low of $44.34 and a 52-week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.35%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.